國家衛生研究院 NHRI:Item 3990099045/11058
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 911027      Online Users : 934
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/11058


    Title: Metformin and helicobacter pylori infection in patients with type 2 diabetes
    Authors: Tseng, CH
    Contributors: National Institute of Environmental Health Sciences
    Abstract: Patients with diabetes have an increased risk of gastric cancer (1,2), and metformin may protect against gastric cancer (3). This study investigated whether metformin might protect against Helicobacter pylori infection, an important risk factor of gastric cancer.The reimbursement database of Taiwan ’ s National Health Insurance was used. Disease diagnoses were based on the ICD-9-CM. Diabetes was coded 250. XX, and H. pylori infection was de fi ned by a diagnostic code of 041.86 plus receiving H. pylori eradication therapy (4). A propensity score (PS)-matched cohort (based on the Greedy 8 → 1 digit match algorithm) (3) comprised 16,060 metformin ever users and 16,060 metformin never users with new-onset diabetes, who were enrolled during 1999 – 2005 and followed up until the end of 2011. Patients with type 1 diabetes, cancer diagnoses, or H. pylori infections at entry or within 6 months of diabetes diagnosis, aged , 25 or . 75 years at entry, or with a follow-up duration , 6 months were not included. PS was derived from covariates including age, sex, occupation, living region, hypertension, dyslipidemia, obesity, nephropathy, eye disease, stroke, ischemic heart disease, peripheral arterial disease, chronic obstructive pulmonary disease, tobacco abuse, alcohol-related diagnoses, heart failure, gingival and periodontal diseases, pneumonia, osteoporosis, tuberculosis infection, disease of pancreas, diseases of esophagus, stomach, and duodenum, Epstein Barr virus infection, hepatitis B virus infection, hepatitis C virus infection, and use of insulin, sulfonylureas, meglitinides, acarbose, rosiglitazone, pioglitazone, ACE inhibitors/ angiotensin receptor blockers, calcium channel blockers, statins, fi brates, and aspirin. Hazard ratios (HRs) were estimated by Cox regression incorporated with the inverse probability of treatment weighting using PS (3). Standardized difference was calculated for each covariate, and a cutoff . 10% may indicate potential confounding (5).
    Date: 2018-02-01
    Relation: Diabetes Care. 2018 Apr;41(4):E42-E43.
    Link to: http://dx.doi.org/10.2337/dc17-2551
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0149-5992&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000428000000002
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85044511976
    Appears in Collections:[Others] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB29437699.pdf523KbAdobe PDF190View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback